Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.
UBS Maintains Neutral on DocuSign, Lowers Price Target to $65
UBS analyst Karl Keirstead maintains DocuSign (NASDAQ:DOCU) with a Neutral and lowers the price target from $70 to $65.
